1. Brd4-bound enhancers drive critical sex differences in glioblastoma
- Author
-
Kfoury, N, Qi, Z, Wilkinson, MN, Broestl, L, Berrett, KC, Moudgil, A, Sankararaman, S, Chen, X, Gertz, J, Mitra, RD, and Rubin, JB
- Abstract
Sex can be an important determinant of cancer phenotype and exploring sex-specific tumor biology holds promise for identifying novel therapeutic targets and new approaches to cancer treatment. In an established model of glioblastoma, we discovered transcriptome-wide sexual dimorphism in gene-expression that was concordant with sex differences in H3K27ac marks, large Brd4-bound enhancer usage, and Brd4 localization to Myc and p53 genomic binding sites. The sex-specific enhancer usage drove sex differences in stem cell function and tumorigenicity. Moreover, male and female GBM cells exhibited opposing responses to pharmacological or genetic inhibition of Brd4. Brd4 knockdown or inhibition decreased male GBM cell clonogenicity and in vivo tumorigenesis, while increasing both in female GBM cells. These results were validated in male and female patient-derived GBM cell lines. Thus, for the first time, Brd4 activity is revealed to drive a sexually dimorphic stem cell and tumorigenic phenotype, resulting in diametrically opposite responses to BET inhibition in male and female glioblastoma cells. This has critical implications for the clinical evaluation and use of BET inhibitors. Statement of significance Sex-specific Brd4 activity is demonstrated to drive sex differences in GBM and render male and female tumor cells differentially sensitive to BET inhibitors. This has critical implications for clinical use of this class of drugs.
- Published
- 2017
- Full Text
- View/download PDF